Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics (NQ: SGMO )

1.610 -0.090 (-5.29%)
Streaming Delayed Price Updated: 12:48 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 563,177
Open 1.660
Bid (Size) 1.610 (22)
Ask (Size) 1.620 (68)
Prev. Close 1.700
Today's Range 1.610 - 1.670
52wk Range 1.580 - 6.420
Shares Outstanding 145,337,046
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. 
Via Benzinga
UBS Group, Credit Suisse And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded mostly lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga

Performance

YTD
-48.73%
-48.73%
1 Month
-43.31%
-43.31%
3 Month
-48.73%
-48.73%
6 Month
-68.06%
-68.06%
1 Year
-72.05%
-72.05%

More News

Read More
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
10 Companies That Had Tons of Money in SVB When It Collapsed
Via InvestorPlace
What 4 Analyst Ratings Have To Say About Sangamo Therapeutics
Via Benzinga
Earnings Preview For Sangamo Therapeutics
Via Benzinga
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 27, 2023
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit
Via Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
There's a Lot of Upside For Emerging Gene-Editing Companies
Via MarketBeat
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week
Via The Motley Fool
Earnings Scheduled For February 22, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Via Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics's Earnings Outlook
Via Benzinga
Earnings Scheduled For November 3, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.